<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379522</url>
  </required_header>
  <id_info>
    <org_study_id>Vitris</org_study_id>
    <nct_id>NCT00379522</nct_id>
  </id_info>
  <brief_title>Vasopressin in Traumatic Hemorrhagic Shock Study</brief_title>
  <official_title>A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Volker Wenzel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present trial is therefore to assess effects of arginine vasopressin vs.
      saline placebo on hospital admission rate (primary end point), as well as hemodynamic
      variables, fluid resuscitation requirements and hospital discharge rate (secondary study end
      points) in presumed traumatic hemorrhagic shock patients with a systolic arterial blood
      pressure &lt;90 mm Hg after 10 min of standard shock treatment. Accordingly, the study reflects
      an add-on design to standard traumatic shock therapy.

      The hypothesis is that both arginine vasopressin and saline placebo have comparable effects
      on hemodynamic variables, fluid resuscitation requirements, and hospital admission and
      discharge rate. The alternative hypothesis is that arginine vasopressin has more beneficial
      effects on hemodynamic variables, fluid resuscitation requirements, and hospital admission
      and discharge rate than saline placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be designed as a multicenter, randomized, placebo-controlled clinical trial
      with blinded assessment of the outcome in a study network with helicopter emergency medical
      service units in Austria, Germany, Switzerland, Italy, Czech Republic and the Netherlands.

      The protocol, information and consent procedure will be approved by the institutional review
      board of each participating center. Since this is a study randomizing unconscious patients
      who are unable to give informed consent at the time of randomization (§43a Emergency study),
      the requirement of informed consent is planned to be waived in accordance with the ethical
      standards of national legislation in Germany, Austria, Switzerland, Italy, Czech Republic and
      the Netherlands and the guidelines for good clinical practice of the European Agency for the
      Evaluation of Medicinal products. Depending on the patient's outcome, either the surviving
      patient, or the patient's family in case of death of the patient or in case that the patient
      survives but remains mentally handicapped will be informed about the trial (see appendix for
      patient information sheet); the protocol specifies that if there are any objections, the
      patient will be withdrawn from the study.

      Treatment assignments of blinded study drugs will be randomly generated by computer in blocks
      of two, with stratification according to center. Before the start of the trial, staff at
      participating centers will be informed about the rationale of the protocol and the study;
      participating centers will be subsequently contacted and visited to ensure proper enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary end point will be hospital admission rate</measure>
    <time_frame>time from trauma to hospital admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic variables</measure>
    <time_frame>time from trauma to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid resuscitation requirements</measure>
    <time_frame>time from trauma to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge rate</measure>
    <time_frame>time from trauma to hospital discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Shock</condition>
  <condition>Hypovolemia</condition>
  <condition>Hemorrhagic Shock</condition>
  <arm_group>
    <arm_group_label>Vasopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vasopressin, 10 I.U./4 ml, Solution for Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline placebo 4 ml, Solution for Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin</description>
    <arm_group_label>Vasopressin</arm_group_label>
    <other_name>Pressyn</other_name>
    <other_name>CPREssin</other_name>
    <other_name>Pitressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline placebo</intervention_name>
    <description>Placebo for arginine vasopressin</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Kochsalz</other_name>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult trauma patients presenting with presumed traumatic hemorrhagic shock (systolic
             arterial blood pressure &lt;90 mm Hg) that does not respond to the first 10 min of
             standard shock treatment [endotracheal intubation, crystalloid-, colloid-, and
             hypertonic saline (up to 4 ml/kg) fluid resuscitation, and catecholamine (ephedrine,
             phenylephrine, norepinephrine, epinephrine) vasopressors].

        Exclusion Criteria:

          -  Terminal illness

          -  No intravenous access

          -  Age &lt; 18 years

          -  Injury &gt; 60 min before randomization

          -  Known pregnancy

          -  Cardiac arrest before randomization

          -  Presence of a do-not-resuscitate order

          -  Untreated tension pneumothorax

          -  Untreated cardiac tamponade

          -  Participation in another clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Volker Wenzel, M.Sc., M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Innsbruck Medical University, Dep. for Anaesthesia and Crit. Care Management</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HEMS Ybbsitz / Hospital Amstetten</name>
      <address>
        <city>Amstetten</city>
        <state>Lower Austria</state>
        <zip>A-3300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Krems</name>
      <address>
        <city>Krems</city>
        <state>Lower Austria</state>
        <zip>A-3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>A-2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Linz</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>A-4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEMS Suben / Landeskrankenhaus Schärding</name>
      <address>
        <city>Schaerding</city>
        <state>Upper Austria</state>
        <zip>A-4780</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG-Unfallklinik Murnau</name>
      <address>
        <city>Murnau</city>
        <zip>D-82418</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Jung-Stilling-Krankenhaus</name>
      <address>
        <city>Siegen</city>
        <zip>D-57074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundeswehrkrankenhaus Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.vitris.at</url>
    <description>Study Homepage</description>
  </link>
  <reference>
    <citation>Krismer AC, Wenzel V, Voelckel WG, Innerhofer P, Stadlbauer KH, Haas T, Pavlic M, Sparr HJ, Lindner KH, Koenigsrainer A. Employing vasopressin as an adjunct vasopressor in uncontrolled traumatic hemorrhagic shock. Three cases and a brief analysis of the literature. Anaesthesist. 2005 Mar;54(3):220-4.</citation>
    <PMID>15605286</PMID>
  </reference>
  <reference>
    <citation>Schummer W, Schummer C, Fuchs J. [Vasopressin]. Anaesthesist. 2005 Jul;54(7):707-8. German.</citation>
    <PMID>15843908</PMID>
  </reference>
  <reference>
    <citation>Tsuneyoshi I, Onomoto M, Yonetani A, Kanmura Y. Low-dose vasopressin infusion in patients with severe vasodilatory hypotension after prolonged hemorrhage during general anesthesia. J Anesth. 2005;19(2):170-3.</citation>
    <PMID>15875138</PMID>
  </reference>
  <reference>
    <citation>Raedler C, Voelckel WG, Wenzel V, Krismer AC, Schmittinger CA, Herff H, Mayr VD, Stadlbauer KH, Lindner KH, Königsrainer A. Treatment of uncontrolled hemorrhagic shock after liver trauma: fatal effects of fluid resuscitation versus improved outcome after vasopressin. Anesth Analg. 2004 Jun;98(6):1759-66, table of contents.</citation>
    <PMID>15155342</PMID>
  </reference>
  <reference>
    <citation>Stadlbauer KH, Wenzel V, Krismer AC, Voelckel WG, Lindner KH. Vasopressin during uncontrolled hemorrhagic shock: less bleeding below the diaphragm, more perfusion above. Anesth Analg. 2005 Sep;101(3):830-2.</citation>
    <PMID>16115999</PMID>
  </reference>
  <reference>
    <citation>Stadlbauer KH, Wagner-Berger HG, Raedler C, Voelckel WG, Wenzel V, Krismer AC, Klima G, Rheinberger K, Nussbaumer W, Pressmar D, Lindner KH, Königsrainer A. Vasopressin, but not fluid resuscitation, enhances survival in a liver trauma model with uncontrolled and otherwise lethal hemorrhagic shock in pigs. Anesthesiology. 2003 Mar;98(3):699-704.</citation>
    <PMID>12606914</PMID>
  </reference>
  <reference>
    <citation>Voelckel WG, Raedler C, Wenzel V, Lindner KH, Krismer AC, Schmittinger CA, Herff H, Rheinberger K, Königsrainer A. Arginine vasopressin, but not epinephrine, improves survival in uncontrolled hemorrhagic shock after liver trauma in pigs. Crit Care Med. 2003 Apr;31(4):1160-5.</citation>
    <PMID>12682488</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University Innsbruck</investigator_affiliation>
    <investigator_full_name>Volker Wenzel</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>hemorrhagic</keyword>
  <keyword>shock</keyword>
  <keyword>traumatic</keyword>
  <keyword>shock treatment</keyword>
  <keyword>vasopressin</keyword>
  <keyword>Circulatory Collapse</keyword>
  <keyword>Hypovolemic Shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Hypovolemia</mesh_term>
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

